Dimerix Ltd (ASX: DXB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Dimerix Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $91.45 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 320.87 million
Earnings per share -0.032
Dividend per share N/A
Year To Date Return 19.15%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Dimerix Ltd (ASX: DXB)
Latest News

DXB ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Dimerix Ltd

A clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix’s lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200

DXB Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
14 Oct 2021 $0.28 $-0.01 -3.57% 252,595 $0.28 $0.28 $0.28
13 Oct 2021 $0.28 $0.01 3.64% 864,608 $0.28 $0.28 $0.27
12 Oct 2021 $0.28 $-0.01 -3.51% 325,990 $0.28 $0.29 $0.28
11 Oct 2021 $0.29 $-0.01 -3.45% 548,047 $0.30 $0.30 $0.28
08 Oct 2021 $0.29 $-0.01 -3.33% 578,931 $0.30 $0.30 $0.29
07 Oct 2021 $0.30 $0.01 3.39% 1,106,010 $0.30 $0.31 $0.30
06 Oct 2021 $0.30 $0.03 11.11% 1,313,526 $0.27 $0.30 $0.26
05 Oct 2021 $0.27 $-0.02 -6.90% 2,271,683 $0.28 $0.28 $0.27
04 Oct 2021 $0.29 $-0.02 -6.45% 1,480,945 $0.31 $0.31 $0.29
01 Oct 2021 $0.31 $0.01 3.33% 386,515 $0.30 $0.31 $0.30
30 Sep 2021 $0.30 $0.00 0.00% 398,691 $0.31 $0.31 $0.30
29 Sep 2021 $0.30 $-0.01 -3.23% 640,484 $0.30 $0.31 $0.30
28 Sep 2021 $0.31 $-0.02 -6.06% 990,976 $0.33 $0.33 $0.31
27 Sep 2021 $0.33 $0.02 6.45% 5,506,420 $0.32 $0.35 $0.30
24 Sep 2021 $0.31 $0.03 10.71% 2,696,474 $0.30 $0.32 $0.29
23 Sep 2021 $0.28 $0.01 3.64% 304,339 $0.28 $0.28 $0.28
22 Sep 2021 $0.28 $-0.01 -3.57% 198,907 $0.28 $0.28 $0.27
21 Sep 2021 $0.28 $0.01 3.64% 494,964 $0.28 $0.29 $0.27
20 Sep 2021 $0.28 $-0.01 -3.57% 603,494 $0.28 $0.29 $0.27
17 Sep 2021 $0.28 $0.00 0.00% 350,208 $0.29 $0.29 $0.28
16 Sep 2021 $0.28 $-0.01 -3.45% 484,825 $0.30 $0.30 $0.28
15 Sep 2021 $0.29 $-0.01 -3.33% 1,233,233 $0.30 $0.31 $0.29

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
05 Oct 2021 James Williams Issued 264 $71,478
Director remuneration.
05 Oct 2021 James Williams Issued 125 $25,000
Issue of securities.
05 Oct 2021 James Williams Issued 62 $16,875
Placement.
05 Oct 2021 Hugh Alsop Issued 167 $45,144
Director remuneration.
05 Oct 2021 Nina Webster Issued 50 $10,000
Issue of securities.
05 Oct 2021 Nina Webster Issued 25 $6,750
Placement.
05 Oct 2021 Sonia Poli Issued 75 $15,000
Issue of securities.
05 Oct 2021 Sonia Poli Issued 37 $10,125
Placement.
05 Oct 2021 Sonia Poli Issued 167 $45,144
Director remuneration.
21 Apr 2021 James Williams Expiry 175 $45,500
Options expired.
21 Apr 2021 Sonia Poli Expiry 125 $32,500
Options expired.
21 Apr 2021 Hugh Alsop Expiry 125 $32,500
Options expired.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr James Howard Williams Non-Executive ChairmanNon-Executive Director Nov 2015
Dr Williams was the CEO of unlisted Dimerix Bioscience Pty Ltd between 2007 and 2009. He is a Founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia and a Director of Yuuwa investee companies PolyActiva Pty Ltd and alternate director of Adalta Limited (ASX:1AD). He is also a Director of the Perron Institute for Neurological and Translational Science, a member of the Panel of Experts for the University of Western Australia's Pathfinder Fund and a member of the Federal Government's Entrepreneur Program Committee.
Mr Hugh Alsop Non-Executive Director May 2017
Mr Aslop is an accomplished and commercially focused executive with experience in international business development, partnering, drug development and leadership of scientific teams. Hugh is currently CEO of Kinoxis Therapeutics. Prior to Kinoxis, he was CEO of venture-backed private company Hatchtech, and Director of Business Development at Acrux Limited (ASX:ACR), where he was responsible for several drug development programs for the international markets. He is also a non-Executive Director of private companies Servatus Ltd and Eflare Corporation Pty Ltd.
Ms Nina Webster Chief Executive OfficerManaging Director Aug 2018
Ms Webster has experience in the pharmaceutical industry, with leadership roles across strategy, commercialisation, intellectual property, scientific and operational aspects of product development. She was formerly the Commercial Director for Acrux Limited (ASX: ACR), developing and commercialising 3 products globally. She has previously worked within Immuron Limited (ASX: IMC), and large Pharma, Wyeth Pharmaceuticals(UK)
Dr Sonia Maria Poli Non-Executive Director Jul 2015
Dr Poli is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. She has served as Chief Scientific Officer at Minoryx and Addex Therapeutics. She was formerly Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics.
Mr Hamish George Chief Financial OfficerCompany Secretary May 2019
-
Hamish George Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Peter Fletcher Meurs 26,529,309 13.40%
Bavaria Bay Pty Ltd 7,316,992 3.70%
Yodambao Pty Ltd <Yodambao Investment A/C> 6,312,603 3.19%
Hsbc Custody Nominees (Australia) Limited 2,587,890 1.31%
Mr Richard Stanley De Ravin 2,200,000 1.11%
Mr James Victor Camilleri 2,178,957 1.10%
Mrs Gwen Murray Pfleger <Pfleger Family A/C> 2,105,988 1.06%
Mr Taylor Nicholas Green 2,100,000 1.06%
Toroha Pty Ltd <The White Family A/C> 2,044,932 1.03%
Solequest Pty Ltd 2,012,302 1.02%
Jampaso Pty Ltd <Williams Family A/C> 1,778,742 0.90%
Mr Rohan Charles Edmondson & Mrs Fionnuala Catherine Edmondson <R F Edmondson Superfund A/C> 1,700,000 0.86%
First Class Services Group Pty Ltd 1,440,000 0.73%
Jezmicktom Pty Ltd 1,285,508 0.65%
Janaka Pty Ltd <The Aitken Family A/C> 1,176,785 0.59%
Goldfire Enterprises Pty Ltd 1,074,657 0.54%
Jgc Super Pty Ltd <Jgc Family Super Fund A/C> 1,073,100 0.54%
Stoneridge Mining Pty Ltd <Stoneridge Mining Unit A/C> 1,050,000 0.53%
J & J Bandy Nominees Pty Ltd <J & J Bandy Super Fund A/C> 1,050,000 0.53%
Dr Martin Marshall 1,000,043 0.51%
Blake Nominees Pty Ltd <M And T Super Fund A/C> 1,000,001 0.51%

Profile

since

Note